Intranasal administration of a synthetic peptide vaccine encapsulated in liposome together with an anti-CD40 antibody induces protective immunity against influenza A virus in mice

Vaccine

Volumn 20, Issue 25-26, 2002, Pages 3123-3129

  Ninomiya, Ai ^a   Ogasawara, Kazumasa ^b   Kajino, Kiichi ^b   Takada, Ayato ^c   Kida, Hiroshi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Intranasal influenza vaccine; Mucosal immunity; Mucosal vaccine adjuvant

Indexed keywords

ANTIBODY; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SYNTHETIC PEPTIDE; VIRUS NUCLEOPROTEIN; BETA 2 MICROGLOBULIN; CD40 ANTIGEN; CORE PROTEIN; EPITOPE; HLA ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; NP PROTEIN; NUCLEOCAPSID PROTEIN; NUCLEOPROTEIN; NUCLEOPROTEIN (366 374), INFLUENZA VIRUS; NUCLEOPROTEIN (366-374), INFLUENZA VIRUS; PEPTIDE FRAGMENT; RECOMBINANT VACCINE; SUBUNIT VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CELL SPECIFICITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG ACTIVITY; FEMALE; INFECTION RESISTANCE; INFLUENZA VIRUS A; INOCULATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; VIRUS REPLICATION; ANIMAL; C57BL MOUSE; CD4+ T LYMPHOCYTE; GENE; GENETICS; IMMUNIZATION; IMMUNOLOGY; INTRANASAL DRUG ADMINISTRATION; KINETICS; LUNG; METHODOLOGY; MOUSE MUTANT; PHYSIOLOGY; VACCINATION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMAL; ANTIBODIES, MONOCLONAL; ANTIGENS, CD40; BETA 2-MICROGLOBULIN; CD4-POSITIVE T-LYMPHOCYTES; EPITOPES; FEMALE; GENES, MHC CLASS II; HISTOCOMPATIBILITY ANTIGENS CLASS II; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, HUMAN; INFLUENZA VACCINE; KINETICS; LIPOSOMES; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NUCLEOPROTEINS; PEPTIDE FRAGMENTS; SUPPORT, NON-U.S. GOV'T; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION; VACCINES, SUBUNIT; VACCINES, SYNTHETIC; VIRAL CORE PROTEINS; VIRUS REPLICATION; ANIMALS; INFLUENZA A VIRUS; INFLUENZA VACCINES; NUCLEOCAPSID PROTEINS;

EID: 0037135673     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00261-X     Document Type: Article

References (41)

1. Modulation of immune responses following antigen administration by mucosal route
2. Recent advances in mucosal vaccine development
3. Enteric immunization reveals a T cell network for IgA responses and suggests that humans possess a common mucosal immune system
4. The common mucosal immune system and current strategies for induction of immune responses in external secretions
5. Vaccines for mucosal immunity to combat emerging infectious diseases
6. + cytotoxic T lymphocyte responses induced in mucosa-associated tissues
7. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge
8. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B
9. The protective efficacy of a liposomal encapsulated 30 kDa secretory protein of mycobacterium tuberculosis H37Ra against tuberculosis in mice
10. Cytokine-containing liposomes as vaccine adjuvants
11. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens
12. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine
13. Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine
14. Liposomal formulation of a self lymphoma antigen induces potent protective anti-tumor immunity
15. Liposomes as carriers of antigens and adjuvants
16. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules
17. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen
18. The CD40 antigen and its ligand
19. + T-helper and a T-killer cell
20. Help for cytotoxic-T-cell responses is mediated by CD40 signalling
21. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions
22. + T cell proliferation and production of IFN-γ in response to p24 antigen in HIV-infected individuals: Potential contribution of energy to HIV-specific unresponsiveness
23. Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1
24. Effective priming of cytotoxic T lymphocyte precursors by subcutaneous administration of peptide antigens in liposomes accompanied by anti-CD40 and anti-CTLA-4 antibodies
25. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse
26. CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge
27. CD40 signaling converts a minimally immunogenic antigen into a potent vaccine against the intracellular pathogen Listeria monocytogenes
28. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help
29. + T-cell tolerance to T-cell priming through in vivo ligation of CD40
30. Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb
31. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy
32. Activation of mitogen-activated protein kinases via CD40 is distinct from that stimulated by surface IgM on B cells
33. A potential peptide vaccine against two different strains of influenza virus isolated at intervals of about 10 years
34. The binding affinity and dissociation rates of peptides for class I major histocompatibility complex molecules
35. Long-lived cytotoxic T lymphocyte memory in mucosal tissues after mucosal but not systemic immunization
36. + cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection
37. + T cells
38. A critical role for CD40-CD40 ligand interactions in amplification of the mucosal CD8 T cell response
39. + cytotoxic T lymphocytes
40. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen
41. Cutting edge: Precursor frequency affects the helper dependence of cytotoxic T cells